Boehringer Ingelheim
For Healthcare Professionals

Document ID: PC-MY-101255

Speaker: Assoc Prof Dr Ho Gwo-Fuang

Effectiveness of Dose Modification Strategies with Afatinib: A Real-World Experience

Watch Assoc Prof Dr Ho Gwo-Fuang, Clinical Oncologist/Radiotherapist, Faculty of Medicine at University of Malaya, Kuala Lumpur, Malaysia share about real-world evidence of persistent efficacy with afatinib dose modification and AE management strategies for continued clinical benefit.

Expert Conversations

Malaysia Region Tumour Heterogeneity in Lung Cancer Asian setting
MYEEE||EGFR TKI-related Dermatological Adverse Events
MYEEE||Evidence for Sequential Therapy in EGFR M+ NSCLC
MYEEE||Effectiveness of Dose Modification Strategies with Afatinib
MYEEE||Strategies in Managing EGFRM+ NSCLC
Malaysia Region Treatment stratergy with EGFR-TKIs Asian setting
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Q&A session)
Running the Marathon: Updated Evidence on Sequential EGFR TKI Approach in NSCLC (Presentation)
MYEEE||PeRsonalized apprOach in Lung adenocarciNoma with EGFR-TKI therapy (PROLONG)
Uncovering the Uncommon: Efficacy of Afatinib in Uncommon and Compound Mutations
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Lecture)
Taking Cancer On Webinar – Let’s TOAST to Maximising Time on EGFR-TKI Therapy (Q&A)

Speaker

my-speaker-Assoc-Prof-Dr-Ho-Gwo-Fuang.png

Assoc Prof Dr Ho Gwo-Fuang

Associate Professor Clinical Oncologist/Radiotherapist Faculty of Medicine Dean's Office Faculty of Medicine University of Malaya Kuala Lumpur Malaysia

RELATED CONTENT